Xencor Inc (XNCR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xencor Inc (XNCR) has a cash flow conversion efficiency ratio of -0.049x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.82 Million) by net assets ($625.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Xencor Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Xencor Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read XNCR current and long-term liabilities for a breakdown of total debt and financial obligations.
Xencor Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xencor Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Holystar Information Technology Co. Ltd. A
SHG:688330
|
0.036x |
|
Ramaco Resources Inc
NASDAQ:METC
|
-0.038x |
|
Abacus Life Inc.
NASDAQ:ABL
|
-0.075x |
|
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SHG:688505
|
0.019x |
|
Luzerner Kantonalbank AG
LSE:0QNU
|
0.004x |
|
PPHE Hotel Group Ltd
F:32P
|
0.024x |
|
Yunnan Nantian Electronics Information Co Ltd
SHE:000948
|
-0.005x |
|
Ripley Corp
SN:RIPLEY
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Xencor Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Xencor Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see XNCR market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $674.03 Million | $-202.19 Million | -0.300x | -335.83% |
| 2023-12-31 | $669.13 Million | $85.11 Million | 0.127x | +277.92% |
| 2022-12-31 | $727.50 Million | $24.48 Million | 0.034x | +246.49% |
| 2021-12-31 | $733.50 Million | $-16.85 Million | -0.023x | -162.84% |
| 2020-12-31 | $572.44 Million | $-5.00 Million | -0.009x | -108.06% |
| 2019-12-31 | $593.20 Million | $64.37 Million | 0.109x | +170.98% |
| 2018-12-31 | $521.68 Million | $-79.76 Million | -0.153x | -28.02% |
| 2017-12-31 | $282.05 Million | $-33.68 Million | -0.119x | -139.63% |
| 2016-12-31 | $313.95 Million | $94.62 Million | 0.301x | +83.58% |
| 2015-12-31 | $162.43 Million | $26.67 Million | 0.164x | +145.59% |
| 2014-12-31 | $59.29 Million | $-21.35 Million | -0.360x | -385.61% |
| 2013-12-31 | $73.53 Million | $-5.45 Million | -0.074x | -113.09% |
| 2012-12-31 | $-19.50 Million | $-11.05 Million | 0.567x | +471.26% |
| 2011-12-31 | $-10.94 Million | $-1.08 Million | 0.099x | -- |
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for t… Read more